Press Releases

11.04.2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

10.29.2024

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

10.23.2024

Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

10.22.2024

U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease

10.15.2024

Tim Buckley Elected to Pfizer’s Board of Directors

10.11.2024

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

10.10.2024

Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial

10.09.2024

Pfizer Declares Fourth-Quarter 2024 Dividend

10.08.2024

Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024

09.25.2024

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

09.20.2024

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

09.17.2024

Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts